No Carolina / NY / Florida
Ph: 561.316.3330

spot_img

Seek Labs Announces Successful Completion of African Swine Fever Virus In Vivo Trial Utilizing CRISPR-based Treatments

The trial, which aimed to replicate and expand an earlier trial, demonstrated pigs infected with ASFV and treated with Seek Labs’ CRISPR-based systems survived longer than untreated infected pigs. Over half of the CRISPR-treated pigs survived beyond the duration of the trial. Observations and data from both studies reveal compelling outcomes where treatment prolonged lifespans of infected pigs compared to control groups.

Society for Vascular Surgery Patient Safety Organization, and the Society for Vascular Medicine, with Support from the American Heart Association, Launch New Vascular Medicine Consult Registry for the Vascular Quality Initiative

Summation

  • The American Heart Association, a global force for longer, healthier lives, has a longstanding commitment to improving systems of care through its quality improvement programs such as its flagship Get With The Guidelines® (GWTG) program, promoting consistent adherence to evidence-based guidelines in hospital and healthcare settings across the U.
  • The Society for Vascular Surgery Patient Safety Organization® (SVS PSO) and the Society for Vascular Medicine (SVM), in collaboration with the American Heart Association® (Association), have introduced the Vascular Medicine Consult Registry for the Vascular Quality Initiative.
  • The Society for Vascular Surgery notes the Registry targets the management of new patients who are being treated medically for Atherosclerotic Carotid Artery Occlusive Disease, Abdominal Aortic Aneurysm, and Peripheral Lower Extremity Arterial Disease due to atherosclerosis or true aneurysm.

The Society for Vascular Surgery Patient Safety Organization® (SVS PSO) and the Society for Vascular Medicine (SVM), in collaboration with the American Heart Association® (Association), have introduced the Vascular Medicine Consult Registry for the Vascular Quality Initiative.

The Society for Vascular Surgery notes the Registry targets the management of new patients who are being treated medically for Atherosclerotic Carotid Artery Occlusive Disease, Abdominal Aortic Aneurysm, and Peripheral Lower Extremity Arterial Disease due to atherosclerosis or true aneurysm.

The VMC will emphasize medication details and dosages, risk factor and lifestyle modifications, non-operative treatments and counseling. The registry’s value centers on the comparative effectiveness of surgery versus medically managing patients with vascular diseases. Features include a web-based platform with real-time reporting.

Drs. Josh Beckman, Marc Bonaca and former Association president Dr. Mark Creager are among those members serving on the VMC Steering Committee to provide scientific expertise and oversight. The team has worked diligently to develop the VQI VMC.

“Vascular diseases are prevalent in the U.S. and other nations, often resulting in significantly higher rates of major adverse cardiovascular events including heart attack, stroke and death.” said John Meiners, chief of mission aligned businesses and healthcare solutions for the American Heart Association. “This collaboration will enable providers to identify the best treatments and medicines to improve quality of life and patient care.”

The American Heart Association, a global force for longer, healthier lives, has a longstanding commitment to improving systems of care through its quality improvement programs such as its flagship Get With The Guidelines® (GWTG) program, promoting consistent adherence to evidence-based guidelines in hospital and healthcare settings across the U.S. This team effort represents an opportunity to leverage the strengths of both organizations to improve care delivered to patients with vascular disease in the outpatient populations as well.

Drs. Randall DeMartino, and Michael R. Jaff of the SVS co-chair the VMC Steering Committee. “This new registry will allow us to compare the full spectrum of treatment options for patients with vascular disease in order to define the best treatment for each patient,” said Dr. DeMartino. Dr. Jaff noted that the new registry enables physicians to have a comprehensive view of a patients’ medical profile. “We can see if we have done enough to keep them healthy. We can understand in greater detail how cardiovascular risk factors are managed and how that impacts patient outcomes,” he said.

Utilizing the M2S PATHWAYS cloud-based platform, the new registry provides real-time tracking of patients and outcomes that can be used for quality improvement at a practitioner and institutional level. Outcomes can be evaluated against regional and national benchmarks. In addition, providers have access to a large database for local, regional and national analysis. The SVS VQI is organized as part of the Society for Vascular Surgery Patient Safety Organization (SVS PSO), which provides protection against discovery of comparative data in legal proceedings. Providers can submit outcome data in a secure environment, as the data will only be used for quality improvement and cannot be publicly reported. Regular audits help ensure data integrity and prevent selective reporting.

“We are extremely excited about the introduction of the Vascular Medicine Consult Registry,” said Jens Jorgensen, MD, Medical Director of the SVS VQI. “The effort and collaboration put into the VMC will provide a necessary platform for physicians to manage, analyze and improve outcomes for patients with peripheral arterial disease being treated with medical therapy. Data generated by the registry will directly support our goal of improving care for medically managed patients.”

SonoVascular Enters Into Strategic Collaboration with Lantheus Holdings | for Use of Microbubbles in Combination with SonoThrombectomy™ System for Treatment of Venous Thromboembolism

"SonoVascular is honored to have the opportunity to partner with Lantheus, a leader in microbubble development," said Daniel Estay, Founder and Chief Executive Officer of SonoVascular. "Our SonoThrombectomy System, combined with Lantheus' microbubbles, is designed to provide a true, next-generation solution for the treatment of DVT and PE that overcomes the drawbacks associated with catheter-based thrombectomy and thrombolysis devices."

Anaut Announces Japanese Regulatory Approval of AI-Powered Surgical Visualization Tool, Eureka α

Eureka α utilizes state-of-the-art AI to analyze real-time video from laparoscopic and robotic surgery, enhancing surgeons' accuracy by highlighting the dissection planes characterized by connective tissue.

Discover Reeva FT: Revolutionizing Wound Covering for Healthcare Pros

Reeva FT is offered in a variety of sizes: 2x2 cm, 2x3 cm, 4x4 cm, 4x6 cm, 4x8 cm, and 10x15 cm. Reeva FT is confirmed by the FDA Tissue Reference Group to meet the criteria for regulation solely under Section 361 of the PHS Act as defined in 21 CFR Part 1271.
Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

By using this website you agree to accept Medical Device News Magazine Privacy Policy